This review is an objective critique of the thoracic outlet syndrome, with emphasis on the need to separate true neurogenic and vascular syndromes from nonspecific ones. Major controversies in the diagnosis and management of thoracic outlet syndromes are discussed, with an analysis of major pitfalls encountered in the diagnosis and treatment of patients with nonspecific syndromes. Recommendations to improve diagnostic methods in patients with chronic neurovascular abnormalities in the upper extremities are outlined.
A 60 year old woman presented in October 1982 with a 6-week history of progressive proximal muscle weakness in the upper and lower limbs. She had smoked 20 cigarettes per day for 40 years. On examination she was found to be emphysematous with generalized hyporeflexia and symmetrical proximal muscle weakness.Electromyographic (EMG) studies revealed normal motor nerve conduction velocities, sensory nerve action potentials, and distal latencies. The compound motor action potential (CMAP) in the right abductor pollicis brevis was 3 mV. Kepetitive stimulation at a rate of 2 Hz produced a 26% decrement in amplitude of the CMAP by the fourth response. Repetitive stimulation at 20 Hz provoked an incremental response of 400% with the CMAP amplitude increasing to 12 mV. Following a 2-minute period of isometric exercise, the CMAP was 4.5 mV, indicative of a degree of postexercise facilitation. The clinical and EMG features were diagnostic of LEMS, and an extensive search was undertaken for a systemic neoplasm without success. Hematological studies were normal. The white blood cell count (WBC) was 6.4 X 10"/L. Treatment was initiated with guanidine hydrochloride at a dose of 125 mg qid (10 mg/kg/day) and a successful response was obtained. The dose was, therefore, increased further to 250 mg qid (20 mg/kg/day), and muscle power returned to near normal.Five weeks after guanidine was commenced, a routine WBC was 3.5 X 10glL (neutrophils 2.27, lymphocytes 0.91). The dose of guanidine was, therefore, reduced to 150 mg qid (12 mg/kg/day).One week later her WBC was 2.8 X 10g/L (neutrophils 1.14, lymphocytes 1.23). Guanidine was ceased immediately, and 36 hours later a sternal bone marrow aspirate was performed, showing an adequate number of granulocytic precursors. N eutrophil antibody studies were negative.Four days after termination of guanidine therapy, the patient's WBC had risen to 6.6 x 1Oy/L (neutrophils 4.3), but she was significantly weaker. Guanidine was re-instituted at 125 mg qid under prednisone cover of 60 mglday. The WBC remained stable, and the prednisone was gradually phased out over 6 weeks.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.